Californian medical device company Nevro has launched AI-driven technology for spinal-cord stimulation that combines insights from over 100,000 patients and more than 100 million data points.

The HFX iQ leverages artificial intelligence (AI) to deliver responsive and personalised pain relief in real time.

The US Food & Drug Administration (FDA) has approved the responsive, personalised pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.

Building on a foundation of evidence, clinical research and big data, HFX AdaptivAI provides patients suffering from chronic pain with personalised, responsive pain relief.

“Nevro is further establishing its position as the leading developer of data-driven options for pain management through the launch of HFX iQ with HFX AdaptivAI,” said Kevin Thornal, Nevro CEO. “HFX AdaptivAI delivers personalised pain relief, utilising AI and leveraging millions of data points and ten years of innovation and patient care. We believe this is a major milestone, and it demonstrates our dedication to freeing patients from the burden of chronic pain through evidence-based therapies that transform patients’ lives. Importantly, HFX AdaptivAI puts patients in control of their pain relief while, at the same time, providing physicians the ability to monitor their patient’s pain journey, closing the loop that matters.”

Usman Latif, an interventional pain specialist at the University of Kansas Health System, added: “HFX AdaptivAI is a significant leap forward in pain management. Drawing from landmark evidence and big data, this technology has the potential to offer patients a faster and more sustainable approach to pain relief. HFX AdaptivAI is on the right path to make a lasting impact on how we manage chronic pain and improve patient outcomes.”

HFX AdaptivAI (nevro.com/English/us/providers/Product-HFX-AdaptivAI) is engineered to increase pain relief over time by continuing to optimise therapy even when pain relief over 50% has been achieved. Proprietary technology creates customised therapy programmes in real time using direct patient input.

Through therapy optimisation, smart power technology lets patients charge their device as little as six times per year.

The technology gathers real-time quality of life (QoL) metrics and device data, enabling more impactful patient-clinician interactions. This real-time information helps patients report pain relief in significantly less time than with traditional programming. Physicians will be able to monitor each of their patient’s pain journey remotely in real time through Nevro’s healthcare provider portal.

“Chronic pain is a dynamic, biopsychosocial human condition unique to each individual,” said David Caraway, Nevro’s chief medical officer. “To effectively treat suffering – as perceived by each patient – therapies must be personalised based on the changing experience of pain. Only HFX AdaptivAI seeks to engage with the patient and personalise the SCS therapy in real time using evidence based on algorithms and multi-dimensional metrics of pain relief, function and satisfaction.”

Headquartered in Redwood City, California, Nevro (www.nevro.com) is a medical device company focused on delivering life-changing options that set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10kHz therapy, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally.

Nevro’s HFX SCS platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy.